STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter
In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover target. The possibility that’s it’s vulnerable to acquisition even sparked a rally in its stock price last week — something the biotech’s own CEO, Dan O’Day, and his newly formed executive team couldn’t manage to do during their disappointing earnings call and 2020 outlook.
So I asked a health care investor what he made of all the talk. Was it legitimate or ridiculous?